NZ539534A

NZ539534A - Selective cytokine inhibitory drugs for treating myelodysplastic syndrome

Selective cytokine inhibitory drugs for treating myelodysplastic syndrome

Info

Publication number: NZ539534A
Authority: NZ; New Zealand
Prior art keywords: carbon atoms; alkyl; cytokine inhibitory; selective cytokine; phenyl
Prior art date: 2002-10-15

Application number

NZ539534A

Other languages

English (en)

Inventor

Jerome B Zeldis

Original Assignee

Celgene Corp

Priority date

2002-10-15

Filing date

2003-04-13

Publication date

2008-06-30

2003-04-13 Application filed by Celgene Corp filed Critical Celgene Corp

2008-06-30 Publication of NZ539534A publication Critical patent/NZ539534A/en

Links

102000004127 Cytokines Human genes 0.000 title claims abstract description 115
108090000695 Cytokines Proteins 0.000 title claims abstract description 115
201000003793 Myelodysplastic syndrome Diseases 0.000 title claims abstract description 114
239000003814 drug Substances 0.000 title claims abstract description 106
230000002401 inhibitory effect Effects 0.000 title claims abstract description 106
229940079593 drug Drugs 0.000 title claims abstract description 103
239000004480 active ingredient Substances 0.000 claims abstract description 67
239000002552 dosage form Substances 0.000 claims abstract description 60
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
238000002560 therapeutic procedure Methods 0.000 claims abstract description 30
238000011282 treatment Methods 0.000 claims abstract description 23
238000004519 manufacturing process Methods 0.000 claims abstract description 18
210000004369 blood Anatomy 0.000 claims abstract description 12
239000008280 blood Substances 0.000 claims abstract description 12
210000000601 blood cell Anatomy 0.000 claims abstract description 10
150000001875 compounds Chemical class 0.000 claims description 83
-1 carbethoxy, carbomethoxy, carbopropoxy, acetyl Chemical group 0.000 claims description 71
125000004432 carbon atom Chemical group C* 0.000 claims description 61
239000000203 mixture Substances 0.000 claims description 61
150000003839 salts Chemical class 0.000 claims description 49
229910052739 hydrogen Inorganic materials 0.000 claims description 40
239000001257 hydrogen Substances 0.000 claims description 40
239000012453 solvate Substances 0.000 claims description 40
125000000217 alkyl group Chemical group 0.000 claims description 36
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
229940080818 propionamide Drugs 0.000 claims description 26
230000000694 effects Effects 0.000 claims description 22
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 18
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 18
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 18
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 17
125000003545 alkoxy group Chemical group 0.000 claims description 16
210000001185 bone marrow Anatomy 0.000 claims description 15
125000004093 cyano group Chemical group *C#N 0.000 claims description 15
229960005280 isotretinoin Drugs 0.000 claims description 14
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 14
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
208000009527 Refractory anemia Diseases 0.000 claims description 12
206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims description 11
239000005517 L01XE01 - Imatinib Substances 0.000 claims description 10
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 10
229960003957 dexamethasone Drugs 0.000 claims description 10
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
125000001424 substituent group Chemical group 0.000 claims description 10
102000003810 Interleukin-18 Human genes 0.000 claims description 9
108090000171 Interleukin-18 Proteins 0.000 claims description 9
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 9
229960003405 ciprofloxacin Drugs 0.000 claims description 9
229960001476 pentoxifylline Drugs 0.000 claims description 9
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 8
108010008165 Etanercept Proteins 0.000 claims description 8
YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims description 8
229960000303 topotecan Drugs 0.000 claims description 8
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 8
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 8
229960002066 vinorelbine Drugs 0.000 claims description 8
230000002411 adverse Effects 0.000 claims description 7
229960000403 etanercept Drugs 0.000 claims description 7
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 7
229960002411 imatinib Drugs 0.000 claims description 7
229960000598 infliximab Drugs 0.000 claims description 7
201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 6
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 6
229960004768 irinotecan Drugs 0.000 claims description 6
210000005259 peripheral blood Anatomy 0.000 claims description 6
239000011886 peripheral blood Substances 0.000 claims description 6
YYQGUWHFXVXQOO-GFCCVEGCSA-N 2-chloro-4-[[3-[(2R)-2-hydroxybutyl]-1-methyl-2-oxobenzimidazol-5-yl]amino]pyridine-3-carbonitrile Chemical compound ClC1=C(C#N)C(=CC=N1)NC1=CC2=C(N(C(N2C[C@@H](CC)O)=O)C)C=C1 YYQGUWHFXVXQOO-GFCCVEGCSA-N 0.000 claims description 5
210000004700 fetal blood Anatomy 0.000 claims description 5
229940125721 immunosuppressive agent Drugs 0.000 claims description 5
239000003018 immunosuppressive agent Substances 0.000 claims description 5
208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 4
125000004442 acylamino group Chemical group 0.000 claims description 4
125000003282 alkyl amino group Chemical group 0.000 claims description 4
239000002246 antineoplastic agent Substances 0.000 claims description 4
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
125000004663 dialkyl amino group Chemical group 0.000 claims description 4
230000002489 hematologic effect Effects 0.000 claims description 4
125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 3
DHKAFTYWTCIWJX-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(N)=O)N1C(=O)C2=CC=CC=C2C1 DHKAFTYWTCIWJX-UHFFFAOYSA-N 0.000 claims description 3
230000003115 biocidal effect Effects 0.000 claims description 3
230000002559 cytogenic effect Effects 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
230000003169 placental effect Effects 0.000 claims description 3
238000007920 subcutaneous administration Methods 0.000 claims description 3
206010067387 Myelodysplastic syndrome transformation Diseases 0.000 claims description 2
206010038272 Refractory anaemia with ringed sideroblasts Diseases 0.000 claims description 2
208000033501 Refractory anemia with excess blasts Diseases 0.000 claims description 2
208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 claims description 2
125000004414 alkyl thio group Chemical group 0.000 claims description 2
238000004458 analytical method Methods 0.000 claims description 2
230000008901 benefit Effects 0.000 claims description 2
238000001574 biopsy Methods 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
238000012544 monitoring process Methods 0.000 claims description 2
208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
229940068196 placebo Drugs 0.000 claims description 2
239000000902 placebo Substances 0.000 claims description 2
208000023933 refractory anemia with excess blasts in transformation Diseases 0.000 claims description 2
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 8
125000001475 halogen functional group Chemical group 0.000 claims 6
108010092408 Eosinophil Peroxidase Proteins 0.000 claims 4
102100028471 Eosinophil peroxidase Human genes 0.000 claims 4
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 4
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 4
229960003048 vinblastine Drugs 0.000 claims 4
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 4
108010002386 Interleukin-3 Proteins 0.000 claims 2
102100039064 Interleukin-3 Human genes 0.000 claims 2
229940079156 Proteasome inhibitor Drugs 0.000 claims 2
239000003207 proteasome inhibitor Substances 0.000 claims 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
238000005070 sampling Methods 0.000 claims 1
238000002054 transplantation Methods 0.000 abstract description 19
210000004027 cell Anatomy 0.000 abstract description 16
230000002265 prevention Effects 0.000 abstract description 4
238000000034 method Methods 0.000 description 39
229940002612 prodrug Drugs 0.000 description 31
239000000651 prodrug Substances 0.000 description 31
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
239000003795 chemical substances by application Substances 0.000 description 23
239000013543 active substance Substances 0.000 description 21
235000018102 proteins Nutrition 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 21
108090000623 proteins and genes Proteins 0.000 description 21
239000000546 pharmaceutical excipient Substances 0.000 description 20
201000010099 disease Diseases 0.000 description 18
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 15
150000002431 hydrogen Chemical group 0.000 description 12
230000004044 response Effects 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 11
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
102000003951 Erythropoietin Human genes 0.000 description 10
108090000394 Erythropoietin Proteins 0.000 description 10
229940105423 erythropoietin Drugs 0.000 description 10
239000003826 tablet Substances 0.000 description 10
206010000830 Acute leukaemia Diseases 0.000 description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
102100040247 Tumor necrosis factor Human genes 0.000 description 9
125000000753 cycloalkyl group Chemical group 0.000 description 9
238000009472 formulation Methods 0.000 description 9
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 9
208000031261 Acute myeloid leukaemia Diseases 0.000 description 8
206010033661 Pancytopenia Diseases 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
125000003118 aryl group Chemical group 0.000 description 8
238000013270 controlled release Methods 0.000 description 8
239000007884 disintegrant Substances 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
125000005843 halogen group Chemical group 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 8
235000019813 microcrystalline cellulose Nutrition 0.000 description 8
239000008108 microcrystalline cellulose Substances 0.000 description 8
229940016286 microcrystalline cellulose Drugs 0.000 description 8
210000001167 myeloblast Anatomy 0.000 description 8
239000006186 oral dosage form Substances 0.000 description 8
239000006201 parenteral dosage form Substances 0.000 description 8
210000000130 stem cell Anatomy 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
208000009329 Graft vs Host Disease Diseases 0.000 description 7
229920000168 Microcrystalline cellulose Polymers 0.000 description 7
229920002472 Starch Polymers 0.000 description 7
239000002253 acid Substances 0.000 description 7
208000024389 cytopenia Diseases 0.000 description 7
210000003743 erythrocyte Anatomy 0.000 description 7
208000024908 graft versus host disease Diseases 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 6
239000002585 base Substances 0.000 description 6
239000011230 binding agent Substances 0.000 description 6
230000001351 cycling effect Effects 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
230000000925 erythroid effect Effects 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
230000003394 haemopoietic effect Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
238000007726 management method Methods 0.000 description 6
230000000069 prophylactic effect Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 5
101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
239000002775 capsule Substances 0.000 description 5
230000002354 daily effect Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000035800 maturation Effects 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
230000009466 transformation Effects 0.000 description 5
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
108010074604 Epoetin Alfa Proteins 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
229920000881 Modified starch Polymers 0.000 description 4
239000008156 Ringer's lactate solution Substances 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
230000009471 action Effects 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
208000007502 anemia Diseases 0.000 description 4
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
239000007894 caplet Substances 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000000945 filler Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
229960001375 lactose Drugs 0.000 description 4
239000008101 lactose Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
229960003433 thalidomide Drugs 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
101150015280 Cel gene Proteins 0.000 description 3
208000031404 Chromosome Aberrations Diseases 0.000 description 3
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010029961 Filgrastim Proteins 0.000 description 3
208000014767 Myeloproliferative disease Diseases 0.000 description 3
201000007224 Myeloproliferative neoplasm Diseases 0.000 description 3
150000007945 N-acyl ureas Chemical class 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
229940121375 antifungal agent Drugs 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
238000010322 bone marrow transplantation Methods 0.000 description 3
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
235000005687 corn oil Nutrition 0.000 description 3
239000002285 corn oil Substances 0.000 description 3
235000012343 cottonseed oil Nutrition 0.000 description 3
239000002385 cottonseed oil Substances 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
229940089118 epogen Drugs 0.000 description 3
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
229940093471 ethyl oleate Drugs 0.000 description 3
VBQUDDWATQWCPP-UHFFFAOYSA-N ethylsulfonylbenzene Chemical class CCS(=O)(=O)C1=CC=CC=C1 VBQUDDWATQWCPP-UHFFFAOYSA-N 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
230000006872 improvement Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
239000008297 liquid dosage form Substances 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
239000000463 material Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
235000019260 propionic acid Nutrition 0.000 description 3
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
229940116176 remicade Drugs 0.000 description 3
108010038379 sargramostim Proteins 0.000 description 3
239000008159 sesame oil Substances 0.000 description 3
235000011803 sesame oil Nutrition 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
229940032147 starch Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
HRYCWEZIWMFEDD-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-3-(4-nitro-1,3-dioxoisoindol-2-yl)-n-phenylmethoxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NOCC=2C=CC=CC=2)N2C(C3=C(C=CC=C3C2=O)[N+]([O-])=O)=O)=C1 HRYCWEZIWMFEDD-UHFFFAOYSA-N 0.000 description 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
206010058314 Dysplasia Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
108010044467 Isoenzymes Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010027906 Monocytosis Diseases 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010041660 Splenomegaly Diseases 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
238000003782 apoptosis assay Methods 0.000 description 2
239000008135 aqueous vehicle Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
229960002903 benzyl benzoate Drugs 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 2
150000004657 carbamic acid derivatives Chemical class 0.000 description 2
150000001720 carbohydrates Chemical group 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000011443 conventional therapy Methods 0.000 description 2
150000003950 cyclic amides Chemical class 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000008356 dextrose and sodium chloride injection Substances 0.000 description 2
239000008355 dextrose injection Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000001361 intraarterial administration Methods 0.000 description 2
230000037041 intracellular level Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
150000002605 large molecules Chemical class 0.000 description 2
229940087875 leukine Drugs 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
238000000465 moulding Methods 0.000 description 2
229940029345 neupogen Drugs 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000002687 nonaqueous vehicle Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
125000002524 organometallic group Chemical group 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
238000010837 poor prognosis Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000005522 programmed cell death Effects 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229930002330 retinoic acid Natural products 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229960001727 tretinoin Drugs 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
239000008136 water-miscible vehicle Substances 0.000 description 2
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
LHMYYQCQGPBDIH-UHFFFAOYSA-N 2-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanamide Chemical compound C1C2=CC=CC=C2C(=O)N1C(C(=O)N)CC1=CC=CC=C1 LHMYYQCQGPBDIH-UHFFFAOYSA-N 0.000 description 1
FZEBPJBRDFXKIH-UHFFFAOYSA-N 2-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanoic acid Chemical compound C1C2=CC=CC=C2C(=O)N1C(C(=O)O)CC1=CC=CC=C1 FZEBPJBRDFXKIH-UHFFFAOYSA-N 0.000 description 1
JJVMWANXAMHGPS-UHFFFAOYSA-N 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindole-1,3-dione Chemical compound COC1=CC=C(C(CS(C)(=O)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 JJVMWANXAMHGPS-UHFFFAOYSA-N 0.000 description 1
RIKZBWUWLKCUNY-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3h-isoindol-1-one Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 RIKZBWUWLKCUNY-UHFFFAOYSA-N 0.000 description 1
JIMIQGNFLBAYNO-UHFFFAOYSA-N 3-(1,3-dioxobenzo[f]isoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC4=CC=CC=C4C=C3C2=O)=O)=C1 JIMIQGNFLBAYNO-UHFFFAOYSA-N 0.000 description 1
UFZWIEHRDSAKPV-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC=CC=C3C2=O)=O)=C1 UFZWIEHRDSAKPV-UHFFFAOYSA-N 0.000 description 1
GSCRRCMZMKJZFP-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-phenylmethoxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NOCC=2C=CC=CC=2)N2C(C3=CC=CC=C3C2=O)=O)=C1 GSCRRCMZMKJZFP-UHFFFAOYSA-N 0.000 description 1
QONJXSUGPNCIKG-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)-n-hydroxy-3-(4-methoxy-3-propan-2-yloxyphenyl)propanamide Chemical compound C1=C(OC(C)C)C(OC)=CC=C1C(CC(=O)NO)N1C(=O)C2=CC=CC=C2C1=O QONJXSUGPNCIKG-UHFFFAOYSA-N 0.000 description 1
OUDWSJIHPUWLQE-UHFFFAOYSA-N 3-(3,4-diethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C(CC(O)=O)N1C(=O)C2=CC=CC=C2C1 OUDWSJIHPUWLQE-UHFFFAOYSA-N 0.000 description 1
OQYFIVKWHLAOKT-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(=O)NO)N1C(=O)C2=CC=CC=C2C1=O OQYFIVKWHLAOKT-UHFFFAOYSA-N 0.000 description 1
XTNHNNYYNNRZIV-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-hydroxy-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(=O)NO)N1C(=O)C2=CC=CC=C2C1 XTNHNNYYNNRZIV-UHFFFAOYSA-N 0.000 description 1
HHRBRFMDLUNNSX-UHFFFAOYSA-N 3-(3-butoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCCCC)=CC(C(CC(N)=O)N2C(C3=CC=CC=C3C2)=O)=C1 HHRBRFMDLUNNSX-UHFFFAOYSA-N 0.000 description 1
AAGICWVGIIDLTO-UHFFFAOYSA-N 3-(3-butoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OCCCC)=CC(C(CC(O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 AAGICWVGIIDLTO-UHFFFAOYSA-N 0.000 description 1
DJGWCAKHYFQWHI-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxobenzo[f]isoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC4=CC=CC=C4C=C3C2=O)=O)C=C1OC1CCCC1 DJGWCAKHYFQWHI-UHFFFAOYSA-N 0.000 description 1
HHVLVKOMFOFNPK-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)-n-hydroxypropanamide Chemical compound COC1=CC=C(C(CC(=O)NO)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 HHVLVKOMFOFNPK-UHFFFAOYSA-N 0.000 description 1
QYOSHOBNEQEKHZ-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OCC)=CC(C(CC(O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 QYOSHOBNEQEKHZ-UHFFFAOYSA-N 0.000 description 1
GGNUZNOYDSSADP-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-n-hydroxy-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC=CC=C3C2)=O)=C1 GGNUZNOYDSSADP-UHFFFAOYSA-N 0.000 description 1
UWQLHYJEPXAAIF-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-n-hydroxy-3-(4-nitro-1,3-dioxoisoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=C(C=CC=C3C2=O)[N+]([O-])=O)=O)=C1 UWQLHYJEPXAAIF-UHFFFAOYSA-N 0.000 description 1
JBOBZXFXFVDGNO-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-n-methoxy-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NOC)N2C(C3=CC=CC=C3C2)=O)=C1 JBOBZXFXFVDGNO-UHFFFAOYSA-N 0.000 description 1
CMBFWNFHRMUSLM-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanamide Chemical compound C1C2=CC=CC=C2C(=O)N1C(CC(=O)N)C1=CC=CC=C1 CMBFWNFHRMUSLM-UHFFFAOYSA-N 0.000 description 1
MQSVZMUVVKVXTQ-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanoic acid Chemical compound C1C2=CC=CC=C2C(=O)N1C(CC(=O)O)C1=CC=CC=C1 MQSVZMUVVKVXTQ-UHFFFAOYSA-N 0.000 description 1
XAWOJFZKIJHZEW-UHFFFAOYSA-N 3-(4,7-difluoro-1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=C(C(=CC=C3F)F)C2=O)=O)=C1 XAWOJFZKIJHZEW-UHFFFAOYSA-N 0.000 description 1
GIWGNYYSCIELPD-UHFFFAOYSA-N 3-(4-acetamido-1,3-dioxoisoindol-2-yl)-3-[4-(difluoromethoxy)-3-ethoxyphenyl]propanamide Chemical compound C1=C(OC(F)F)C(OCC)=CC(C(CC(N)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 GIWGNYYSCIELPD-UHFFFAOYSA-N 0.000 description 1
LVGHSBVWSORFEX-UHFFFAOYSA-N 3-(4-amino-1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=C(N)C=CC=C3C2=O)=O)=C1 LVGHSBVWSORFEX-UHFFFAOYSA-N 0.000 description 1
XTEVFIVUZLSJHJ-UHFFFAOYSA-N 3-(4-methoxy-3-propoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCCC)=CC(C(CC(N)=O)N2C(C3=CC=CC=C3C2)=O)=C1 XTEVFIVUZLSJHJ-UHFFFAOYSA-N 0.000 description 1
ASXKYGLTYKLCLZ-UHFFFAOYSA-N 3-(5-amino-1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC(N)=CC=C3C2=O)=O)=C1 ASXKYGLTYKLCLZ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
206010058956 Bicytopenia Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000004358 Butane-1, 3-diol Substances 0.000 description 1
102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
108010065524 CD52 Antigen Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
108010020326 Caspofungin Proteins 0.000 description 1
206010008805 Chromosomal abnormalities Diseases 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
206010067477 Cytogenetic abnormality Diseases 0.000 description 1
102000009058 Death Domain Receptors Human genes 0.000 description 1
108010049207 Death Domain Receptors Proteins 0.000 description 1
108010002156 Depsipeptides Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
108010081348 HRT1 protein Hairy Proteins 0.000 description 1
102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
102000026633 IL6 Human genes 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229910004679 ONO2 Inorganic materials 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
229920000297 Rayon Polymers 0.000 description 1
241000219061 Rheum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229940123468 Transferase inhibitor Drugs 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940091181 aconitic acid Drugs 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
125000004945 acylaminoalkyl group Chemical group 0.000 description 1
125000005041 acyloxyalkyl group Chemical group 0.000 description 1
239000008272 agar Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
229950010817 alvocidib Drugs 0.000 description 1
229960001097 amifostine Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000006427 angiogenic response Effects 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
229960002594 arsenic trioxide Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
231100001018 bone marrow damage Toxicity 0.000 description 1
229960005520 bryostatin Drugs 0.000 description 1
MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
229960000730 caspofungin acetate Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940073621 enbrel Drugs 0.000 description 1
229960003388 epoetin alfa Drugs 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960004177 filgrastim Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000020375 flavoured syrup Nutrition 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000011888 foil Substances 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000007897 gelcap Substances 0.000 description 1
229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
102000046157 human CSF2 Human genes 0.000 description 1
102000044890 human EPO Human genes 0.000 description 1
239000003906 humectant Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940074928 isopropyl myristate Drugs 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
229940059904 light mineral oil Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
BPBRDDCTMUGRTO-UHFFFAOYSA-N methyl 3-(3-butoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoate Chemical compound C1=C(OC)C(OCCCC)=CC(C(CC(=O)OC)N2C(C3=CC=CC=C3C2)=O)=C1 BPBRDDCTMUGRTO-UHFFFAOYSA-N 0.000 description 1
MBRFGSOSVRLYHU-UHFFFAOYSA-N methyl 3-(3-ethoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoate Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)OC)N2C(C3=CC=CC=C3C2)=O)=C1 MBRFGSOSVRLYHU-UHFFFAOYSA-N 0.000 description 1
OWDLKUNGWLGJFD-UHFFFAOYSA-N methyl 3-(4-methoxy-3-propoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoate Chemical compound C1=C(OC)C(OCCC)=CC(C(CC(=O)OC)N2C(C3=CC=CC=C3C2)=O)=C1 OWDLKUNGWLGJFD-UHFFFAOYSA-N 0.000 description 1
RXODVOZOQUCBKM-UHFFFAOYSA-N methyl 3-[4-(cyclopropanecarbonylamino)-3-oxo-1h-isoindol-2-yl]-3-[4-(difluoromethoxy)-3-ethoxyphenyl]propanoate Chemical compound C1=C(OC(F)F)C(OCC)=CC(C(CC(=O)OC)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 RXODVOZOQUCBKM-UHFFFAOYSA-N 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000008747 mitogenic response Effects 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
HIGCSNAMVFZOAQ-UHFFFAOYSA-N n-[2-[3-amino-1-[4-(difluoromethoxy)-3-ethoxyphenyl]-3-oxopropyl]-7-chloro-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC(F)F)C(OCC)=CC(C(CC(N)=O)N2C(C3=C(C(=CC=C3NC(=O)C3CC3)Cl)C2)=O)=C1 HIGCSNAMVFZOAQ-UHFFFAOYSA-N 0.000 description 1
YENYTUWIKANDNM-UHFFFAOYSA-N n-[3-amino-3-(3,4-dimethoxyphenyl)propanoyl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N)CC(=O)NC(=O)C1=CC=CC=C1 YENYTUWIKANDNM-UHFFFAOYSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229960000435 oblimersen Drugs 0.000 description 1
MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
239000006014 omega-3 oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229950009215 phenylbutanoic acid Drugs 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
125000005633 phthalidyl group Chemical group 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229960000540 polacrilin potassium Drugs 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
229950009213 rubitecan Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229960002530 sargramostim Drugs 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
229940126586 small molecule drug Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008354 sodium chloride injection Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229960002232 sodium phenylbutyrate Drugs 0.000 description 1
VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000007905 soft elastic gelatin capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229940066765 systemic antihistamines substituted ethylene diamines Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
229940107955 thymoglobulin Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
239000003558 transferase inhibitor Substances 0.000 description 1
230000007704 transition Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
229950010147 troxacitabine Drugs 0.000 description 1
RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical group O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
OGUJBRYAAJYXQP-IJFZAWIJSA-N vuw370o5qe Chemical compound CC(O)=O.CC(O)=O.C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OGUJBRYAAJYXQP-IJFZAWIJSA-N 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1